Ipca Laboratories Limited has issued a newspaper notice regarding the re-lodgement of a transfer request for physical shares, in compliance with SEBI regulations. The pharmaceutical company filed this notice with BSE Limited and National Stock Exchange of India Limited on April 2, 2026, as mandated under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Share Transfer Details

The transfer request involves securities originally held by Sunil Patel, which are being claimed by Ms. Neha Varshini Patel. According to the company's notice, Ms. Neha Varshini Patel, residing at 1, Ambica Society, Umratnagar, Ahmedabad-380013, has submitted the required documentation including the share certificate and old share transfer form.

Regulatory Compliance Process

The notice follows SEBI Circular SEBI/HO/MIRSD/DOES/CR/R/2018/139 dated November 6, 2018, and SEBI Circular SEBI/HO/MIRSD/MIRSD/CR/P/CR/2025/87 dated July 2, 2025. These regulations govern the transfer of physical shares and require companies to publish public notices for such transactions.

Ms. Neha Varshini Patel has claimed that the securities were gifted to her but could not be transferred to her name earlier. The company noted that the face value of equity shares has since been sub-divided from Rs.10/- to Rs.1/- each.

Claims and Timeline

Ipca Laboratories has established a 30-day period from the date of publication for any person with claims regarding the mentioned securities. Claimants must lodge their claims at the company's registered office along with appropriate documentary evidence. The company has warned that if no valid claims are received within this timeframe, it will proceed to transfer the securities to Ms. Neha Varshini Patel and issue the necessary entitlement letter without further intimation.

Corporate Communication

The notice was signed by Harish P. Kamath, Corporate Counsel & Company Secretary of Ipca Laboratories Limited. The communication was filed through online filing and published in Business Standard and Navshakti newspapers as required by regulatory guidelines. This transparent process ensures compliance with SEBI's disclosure requirements while protecting the interests of all stakeholders involved in the share transfer process.

IPCA Laboratories recorded a significant block trade on the National Stock Exchange (NSE), marking substantial institutional activity in the pharmaceutical company's shares. The large-scale transaction reflects considerable investor interest in the stock.

Block Trade Details

The NSE block trade executed for IPCA Laboratories involved substantial volume and value, demonstrating active participation from institutional investors.

Market Significance

Block trades typically involve large institutional investors, including mutual funds, insurance companies, or foreign institutional investors. Such transactions are executed outside the regular market to avoid impacting the stock's market price during normal trading hours.

The execution price of ₹1,589.00 per share for this block deal provides insight into the institutional valuation of IPCA Laboratories stock. The substantial volume of 381,656 shares indicates significant institutional portfolio adjustments or strategic positioning in the pharmaceutical sector.

Transaction Impact

This block trade represents a noteworthy development in IPCA Laboratories' secondary market activity. The ₹60.65 crore transaction value underscores the scale of institutional interest in the company's shares and reflects active trading among large investors in the pharmaceutical space.